Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Interest Expenses (2020 - 2022)

Inhibikase Therapeutics (IKT) has disclosed Interest Expenses for 3 consecutive years, with $5.0 as the latest value for Q1 2022.

  • On a quarterly basis, Interest Expenses fell 99.96% to $5.0 in Q1 2022 year-over-year; TTM through Dec 2022 was $5.0, a 99.97% decrease, with the full-year FY2021 number at $19923.0, down 32.24% from a year prior.
  • Interest Expenses was $5.0 for Q1 2022 at Inhibikase Therapeutics, down from $158.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $11797.0 in Q1 2021 to a low of $5.0 in Q1 2022.
  • A 3-year average of $5481.1 and a median of $7139.0 in 2020 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: skyrocketed 58.88% in 2021, then tumbled 99.96% in 2022.
  • Inhibikase Therapeutics' Interest Expenses stood at $7139.0 in 2020, then crashed by 97.79% to $158.0 in 2021, then tumbled by 96.84% to $5.0 in 2022.
  • Per Business Quant, the three most recent readings for IKT's Interest Expenses are $5.0 (Q1 2022), $158.0 (Q4 2021), and $157.0 (Q3 2021).